June 2010
"PlantForm has the potential to be a leader in the expanding market for biosimilar antibody drugs. It has proprietary technology capable of making complex human antibodies quickly and inexpensively. It also has a management team with the industry experience necessary for success." John Connolly,
PlantForm investor
Managing Director,
York Medtech Partners
Industry news Amgen 'primed for acquisitions' U.S.-based Amgen is on the lookout for quality pharma companies at the right price, the
Financial Times reports.
Pfizer ramps up biologics Pfizer is partnering with smaller companies on second-generation biologics for a market that could grow to $187B by 2014, the
Wall Street Journal reports.
Europe cuts drug spending European governments are slashing spending on pharmaceuticals to reel in budget deficits, the
Wall Street Journal reports.
Management Team
Don Stewart, PhD President & CEO
Ron Hosking, CA Chief Financial Officer
Chris Hall, PhD Chief Scientific Officer
Board of Directors Mark Goldberg, PhD (Chair) Founder & Director R&D
GlobalTox, a division of MTE Consultants Inc.
Jim Rae CEO, Viron Therapeutics
Warren Whitehead former CFO, Arius Research
Chris Hall, PhD CSO, PlantForm Corp.
Don Stewart, PhD President & CEO, PlantForm Corp.